SEC Comment Letter 0000000000-24-006546 to GridAI Technologies Corp. (GRDX)
GridAI Technologies Corp.
Date: June 6, 2024 · CIK: 0001604191 · Accession: 0000000000-24-006546
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-279896
Letter
United States securities and exchange commission logo June 6, 2024 James Sapirstein Chief Executive Officer Entero Therapeutics, Inc. 777 Yamato Road, Suite 502 Boca Raton, FL 33431 Re:Entero Therapeutics, Inc. Registration Statement on Form S-3 Filed May 31, 2024 File No. 333-279896 Dear James Sapirstein: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jessica Yuan
Show Raw Text
United States securities and exchange commission logo
June 6, 2024
James Sapirstein
Chief Executive Officer
Entero Therapeutics, Inc.
777 Yamato Road, Suite 502
Boca Raton, FL 33431
Re:Entero Therapeutics, Inc.
Registration Statement on Form S-3
Filed May 31, 2024
File No. 333-279896
Dear James Sapirstein:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jessica Yuan